Nutraceuticals manufacturer NatureWell, Incorporated announced recently that a trial conducted on its MigraSpray products suggests that the product has an effect on migraine pain.
According to NatureWell, the randomised, placebo-controlled trial clinical trial demonstrated that the average time for relieving the MigraSpray Group was just over six minutes.
NatureWell claims that the strength of the trial includes the design (baseline headache measurements, specific protocols, randomisation, placebo-controlled, blinding, nursing assessments, cross-over's), outside review, drawn from a general population, a high safety record, equal baseline characteristics between the two groups (placebo and product), and statistical significance in all the major end-point categories. The results of this study are believed to be statistically significant, at a P Value of less than 0.01 in all parameters.
A copy of the clinical trial can be obtained at the company's website, www.naturewell.com